US5223499A
(en)
*
|
1989-05-30 |
1993-06-29 |
Merck & Co., Inc. |
6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
|
US5332744A
(en)
*
|
1989-05-30 |
1994-07-26 |
Merck & Co., Inc. |
Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
|
IE70593B1
(en)
*
|
1989-09-29 |
1996-12-11 |
Eisai Co Ltd |
Biphenylmethane derivative the use of it and pharmacological compositions containing same
|
US5196444A
(en)
*
|
1990-04-27 |
1993-03-23 |
Takeda Chemical Industries, Ltd. |
1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
|
DE4036706A1
(de)
*
|
1990-11-17 |
1992-05-21 |
Hoechst Ag |
Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
|
GB9027198D0
(en)
*
|
1990-12-14 |
1991-02-06 |
Smithkline Beecham Plc |
Medicaments
|
GB9027208D0
(en)
*
|
1990-12-14 |
1991-02-06 |
Smithkline Beecham Plc |
Medicaments
|
SI9210098B
(sl)
*
|
1991-02-06 |
2000-06-30 |
Dr. Karl Thomae |
Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
|
FR2673427B1
(fr)
*
|
1991-03-01 |
1993-06-18 |
Sanofi Elf |
Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
|
TW274551B
(de)
*
|
1991-04-16 |
1996-04-21 |
Takeda Pharm Industry Co Ltd |
|
IL102183A
(en)
*
|
1991-06-27 |
1999-11-30 |
Takeda Chemical Industries Ltd |
The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
|
GB9201789D0
(en)
*
|
1992-01-28 |
1992-03-11 |
Fujisawa Pharmaceutical Co |
Heterocyclic derivatives
|
US5354759A
(en)
*
|
1991-09-12 |
1994-10-11 |
Fujisawa Pharmaceutical Co., Ltd. |
Angiotenin II antagonizing heterocyclic compounds
|
JP2682353B2
(ja)
*
|
1991-11-20 |
1997-11-26 |
武田薬品工業株式会社 |
経口用医薬組成物およびその製造法
|
TW284688B
(de)
*
|
1991-11-20 |
1996-09-01 |
Takeda Pharm Industry Co Ltd |
|
DE4203872A1
(de)
*
|
1992-02-11 |
1993-08-12 |
Thomae Gmbh Dr K |
Imidazo(1,2-a)pyridine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
|
JPH07507271A
(ja)
*
|
1992-03-03 |
1995-08-10 |
藤沢薬品工業株式会社 |
アンジオテンシン11拮抗剤としてのベンズイミダゾール誘導体
|
US5310929A
(en)
*
|
1992-08-06 |
1994-05-10 |
E. I. Du Pont De Nemours And Company |
Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
|
US5266583A
(en)
*
|
1992-09-01 |
1993-11-30 |
Merck & Co., Inc. |
Angitotensin II antagonist
|
DK154092D0
(da)
*
|
1992-12-23 |
1992-12-23 |
Neurosearch As |
Imidazolforbindelser, deres fremstilling og anvendelse
|
US5605919A
(en)
*
|
1993-02-26 |
1997-02-25 |
Takeda Chemical Industries, Ltd. |
Treatment for viral diseases
|
CA2115985A1
(en)
*
|
1993-02-25 |
1994-08-26 |
Kohei Nishikawa |
Vascular hypertrophy suppressor
|
JP3810020B2
(ja)
*
|
1993-04-22 |
2006-08-16 |
武田薬品工業株式会社 |
腎疾患の予防または治療剤
|
JP2003306432A
(ja)
*
|
1993-04-22 |
2003-10-28 |
Takeda Chem Ind Ltd |
腎疾患の予防または治療剤
|
US5721263A
(en)
*
|
1993-06-07 |
1998-02-24 |
Takeda Chemical Industries, Ltd. |
Pharmaceutical composition for angiotensin II-mediated diseases
|
JP3057471B2
(ja)
*
|
1993-06-07 |
2000-06-26 |
武田薬品工業株式会社 |
アンジオテンシンii介在性諸疾患の予防または治療剤
|
CA2125251C
(en)
*
|
1993-06-07 |
2005-04-26 |
Yoshiyuki Inada |
A pharmaceutical composition for angiotensin ii-mediated diseases
|
CZ154994A3
(en)
*
|
1993-07-02 |
1995-09-13 |
Senju Pharma Co |
Visual hypotensive agent
|
US5391566A
(en)
*
|
1993-07-20 |
1995-02-21 |
Merck & Co., Inc. |
Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
|
ZA945190B
(en)
*
|
1993-07-30 |
1995-02-24 |
Kotobuki Seiyaku Co Ltd |
Carboxymethylidenecycloheptimidazole derivatives method or manufacturing the same and therapeutic agents containing these compounds
|
US5824696A
(en)
*
|
1993-09-01 |
1998-10-20 |
Smithkline Beecham Corporation |
Medicaments
|
US6676967B1
(en)
*
|
1993-09-20 |
2004-01-13 |
Kos Pharmaceuticals, Inc. |
Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
|
ES2147798T3
(es)
*
|
1994-01-28 |
2000-10-01 |
Takeda Chemical Industries Ltd |
Un procedimiento para la produccion de compuestos de tetrazolilo.
|
DE4408497A1
(de)
*
|
1994-03-14 |
1995-09-21 |
Thomae Gmbh Dr K |
Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
RU2123847C1
(ru)
*
|
1994-03-16 |
1998-12-27 |
Санкио Компани Лимитед |
Лекарственное средство и способ лечения повышенного глазного давления и/или глаукомы
|
AU677702B2
(en)
*
|
1994-10-13 |
1997-05-01 |
Takeda Pharmaceutical Company Limited |
A prophylactic or therapeutic drug for renal diseases
|
SE9501881D0
(sv)
*
|
1995-05-19 |
1995-05-19 |
Astra Ab |
New pharmacological use of AII-receptor antagonists
|
SE9502219D0
(sv)
*
|
1995-06-19 |
1995-06-19 |
Astra Ab |
Novel medical use
|
ATE225657T1
(de)
*
|
1995-10-06 |
2002-10-15 |
Novartis Erfind Verwalt Gmbh |
Ati-rezeptorantagonisten zur verhinderung und behandlung des postischemischen nervenversagens und zum schutze ischemischer nieren
|
EA002357B1
(ru)
*
|
1995-12-28 |
2002-04-25 |
Фудзисава Фармасьютикал Ко., Лтд. |
Производные бензимидазола
|
DE69718146T2
(de)
|
1996-02-29 |
2003-10-02 |
Novartis Ag |
At1 rezeptor antagonist zur anregung von apoptosis
|
KR19990087076A
(ko)
*
|
1996-04-05 |
1999-12-15 |
다께다 구니오 |
안지오텐신 ⅱ 및 길항 활성을 갖는 화합물을 함유하는 약제학적 배합물
|
US5771604A
(en)
*
|
1997-04-07 |
1998-06-30 |
Maytag Corporation |
Clothes dryer air inlet arrangement
|
US6177587B1
(en)
|
1997-05-26 |
2001-01-23 |
Takeda Chemical Industries, Ltd. |
Production method of aminobenzene compound
|
TW453999B
(en)
|
1997-06-27 |
2001-09-11 |
Fujisawa Pharmaceutical Co |
Benzimidazole derivatives
|
CA2677910C
(en)
|
1997-10-17 |
2011-03-15 |
Ark Therapeutics Limited |
The use of inhibitors of the renin-angiotensin system for the treatment of cardiovascular diseases
|
CA2321110A1
(en)
|
1998-02-23 |
1999-08-26 |
Hiroshi Maruoka |
Benzimidazole derivative
|
DE19820151A1
(de)
*
|
1998-05-06 |
1999-11-11 |
Hexal Ag |
Transdermales therapeutisches System zur Anwendung von Candesartan
|
US6638937B2
(en)
|
1998-07-06 |
2003-10-28 |
Bristol-Myers Squibb Co. |
Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
|
BR9912098A
(pt)
|
1998-07-15 |
2001-09-25 |
Teijin Ltd |
Derivado de tiobenzimidazol, composição farmacêutica, e, agente preventivo e/ou terapêutico
|
CZ297795B6
(cs)
|
1998-12-23 |
2007-03-28 |
Novartis Ag |
Tablety obsahující valsartan
|
US6465502B1
(en)
|
1998-12-23 |
2002-10-15 |
Novartis Ag |
Additional therapeutic use
|
CN101011390A
(zh)
|
1999-01-26 |
2007-08-08 |
诺瓦提斯公司 |
血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
|
GB0001662D0
(en)
*
|
1999-02-06 |
2000-03-15 |
Zeneca Ltd |
Pharmaceutical compositions
|
EP1153613B1
(de)
*
|
1999-02-19 |
2010-11-10 |
Takeda Pharmaceutical Company Limited |
Präparationen zur perkutanen aufnahme von zusammnesetzungen die einen angiotensin-ii-rezeptorantagonismus aufweisen
|
US6211217B1
(en)
|
1999-03-16 |
2001-04-03 |
Novartis Ag |
Method for reducing pericardial fibrosis and adhesion formation
|
DZ3252A1
(de)
*
|
1999-06-10 |
2000-12-21 |
Warner Lambert Co |
|
US6972287B1
(en)
|
1999-06-10 |
2005-12-06 |
Pfizer Inc. |
Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
|
DE60037192T2
(de)
|
1999-07-21 |
2008-05-15 |
Takeda Pharmaceutical Co. Ltd. |
Mittel zur verbesserung der erkrankungen nach zerebralen durchblutungsstörungen sowie zur verhinderung deren fortschreitens
|
SE9903028D0
(sv)
*
|
1999-08-27 |
1999-08-27 |
Astra Ab |
New use
|
PL353199A1
(en)
*
|
1999-08-30 |
2003-11-03 |
Aventis Pharma Deutschland Gmbh |
Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
|
EP1262180A4
(de)
|
2000-02-18 |
2005-06-01 |
Takeda Pharmaceutical |
Tnf-alpha hemmer
|
SE0002353D0
(sv)
*
|
2000-06-22 |
2000-06-22 |
Astrazeneca Ab |
New use
|
CA2417635C
(en)
*
|
2000-08-11 |
2008-02-05 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Heterocyclic compounds useful as inhibitors of tyrosine kinases
|
PE20020617A1
(es)
|
2000-08-22 |
2002-08-05 |
Novartis Ag |
Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
|
AU2001284413A1
(en)
*
|
2000-08-30 |
2002-03-13 |
Sankyo Company Limited |
Medicinal compositions for preventing or treating heart failure
|
CA2426674A1
(en)
*
|
2000-10-25 |
2002-05-02 |
Takeda Chemical Industries, Ltd. |
Agent for preventing or treating portal hypertension
|
US8168616B1
(en)
|
2000-11-17 |
2012-05-01 |
Novartis Ag |
Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
|
EP2062593A3
(de)
|
2000-12-01 |
2011-08-17 |
Takeda Pharmaceutical Company Limited |
Verfahren zur Herstellung einer Zubereitung mit bioaktiven Peptiden
|
WO2003014112A1
(fr)
*
|
2001-08-03 |
2003-02-20 |
Takeda Chemical Industries, Ltd. |
Cristal et procede de fabrication correspondant
|
NZ531346A
(en)
*
|
2001-08-28 |
2005-10-28 |
Sankyo Co |
Medicinal compositions containing angiotensin II receptor antagonist
|
US7107198B2
(en)
*
|
2001-11-02 |
2006-09-12 |
Sun Microsystems, Inc. |
Automatic generation of reduced-size circuit models including inductive interaction
|
CA2466659A1
(en)
|
2001-11-13 |
2003-05-22 |
Takeda Chemical Industries, Ltd. |
Anticancer agents
|
DE10205335A1
(de)
*
|
2002-02-07 |
2003-08-21 |
Bdd Group Holding Ag Zug |
Deuterierte biphenylsubstituierte Benzimidazole sowie diese Verbindungen enthaltende Arzneimittel
|
WO2003074008A2
(en)
*
|
2002-03-01 |
2003-09-12 |
Merck & Co., Inc. |
Aminoalkylphosphonates and related compounds as edg receptor agonists
|
US7232828B2
(en)
|
2002-08-10 |
2007-06-19 |
Bethesda Pharmaceuticals, Inc. |
PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
|
CN1681495B
(zh)
|
2002-08-19 |
2010-05-12 |
辉瑞产品公司 |
用于治疗过度增生性疾病的组合物
|
DE10335027A1
(de)
|
2003-07-31 |
2005-02-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verwendung von Angiotensin II Rezeptor Antagonisten
|
DE602004013405T2
(de)
*
|
2003-03-17 |
2009-05-07 |
Teva Pharmaceutical Industries Ltd. |
Polymorphe formen von valsartan
|
AU2003230193A1
(en)
*
|
2003-03-27 |
2004-10-18 |
Hetero Drugs Limited |
Novel crystalline forms of candesartan cilexetil
|
SE0300988D0
(sv)
*
|
2003-04-03 |
2003-04-03 |
Astrazeneca Ab |
New use
|
WO2004094391A2
(en)
|
2003-04-21 |
2004-11-04 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation of valsartan and intermediates thereof
|
US7732162B2
(en)
|
2003-05-05 |
2010-06-08 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
|
GB0316546D0
(en)
*
|
2003-07-15 |
2003-08-20 |
Novartis Ag |
Process for the manufacture of organic compounds
|
US20050037063A1
(en)
*
|
2003-07-21 |
2005-02-17 |
Bolton Anthony E. |
Combined therapies
|
EP1658281B1
(de)
*
|
2003-08-27 |
2010-09-29 |
Zentiva, k.s. |
Verfahren zur entfernung der triphenylmethanschutzgruppe
|
GB0322552D0
(en)
*
|
2003-09-26 |
2003-10-29 |
Astrazeneca Uk Ltd |
Therapeutic treatment
|
WO2005030202A1
(en)
*
|
2003-09-26 |
2005-04-07 |
Novartis Ag |
Use of angiotensin ii receptor antagonists for treating cerebrovascular disorders
|
CA2542499A1
(en)
*
|
2003-10-16 |
2005-04-28 |
Teva Pharmaceutical Industries Ltd. |
Preparation of candesartan cilexetil
|
US20070292498A1
(en)
*
|
2003-11-05 |
2007-12-20 |
Warren Hall |
Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
|
EP2428516A1
(de)
|
2003-11-19 |
2012-03-14 |
Metabasis Therapeutics, Inc. |
Neue Phosphor enthaltende Thyromimetika
|
WO2005051928A1
(en)
*
|
2003-11-28 |
2005-06-09 |
Ranbaxy Laboratories Limited |
Process for production of tetrazolyl compounds
|
GB0327839D0
(en)
|
2003-12-01 |
2003-12-31 |
Novartis Ag |
Organic compounds
|
JP2005206603A
(ja)
*
|
2004-01-21 |
2005-08-04 |
Teva Pharmaceutical Industries Ltd |
カンデサルタンシレキセチルの調製
|
GB0402262D0
(en)
|
2004-02-02 |
2004-03-10 |
Novartis Ag |
Process for the manufacture of organic compounds
|
US7692023B2
(en)
*
|
2004-02-11 |
2010-04-06 |
Teva Pharmaceutical Industries Ltd. |
Candesartan cilexetil polymorphs
|
US7157584B2
(en)
*
|
2004-02-25 |
2007-01-02 |
Takeda Pharmaceutical Company Limited |
Benzimidazole derivative and use thereof
|
US20080161321A1
(en)
|
2004-03-17 |
2008-07-03 |
David Louis Feldman |
Use of Renin Inhibitors in Therapy
|
JP2007532677A
(ja)
*
|
2004-04-16 |
2007-11-15 |
サンタラス インコーポレイティッド |
プロトンポンプ阻害剤、緩衝剤、および運動促進薬の組み合わせ
|
EP1742938A1
(de)
*
|
2004-05-05 |
2007-01-17 |
Teva Pharmaceutical Industries Ltd. |
Herstellung von hochreinem cadesartan-cilexetil
|
JP2005330277A
(ja)
*
|
2004-05-19 |
2005-12-02 |
Teva Pharmaceutical Industries Ltd |
カンデサルタンシレキセチル多形体
|
JP2009185060A
(ja)
*
|
2004-05-19 |
2009-08-20 |
Teva Pharmaceutical Industries Ltd |
カンデサルタンシレキセチル多形体
|
WO2005117591A2
(en)
*
|
2004-05-28 |
2005-12-15 |
Andrx Labs Llc |
Novel pharmaceutical formulation containing a biguanide and an angiotensin antagonist
|
WO2005123720A1
(en)
*
|
2004-06-18 |
2005-12-29 |
Ranbaxy Laboratories Limited |
Fine particles of the angiotensin ii antagonist candesartan cilexetil and process for production thereof
|
CN101044127A
(zh)
|
2004-08-23 |
2007-09-26 |
惠氏公司 |
用作纤溶酶原激活剂抑制剂-1的噻唑基-萘基酸
|
RU2007106868A
(ru)
|
2004-08-23 |
2008-09-27 |
Вайет (Us) |
Оксазол-нафтиловые кислоты и их применение в качестве модуляторов ингибитора активатора плазминогена-1 (pai) для лечения тромбоза и сердечно-сосудистых заболеваний
|
BRPI0514549A
(pt)
|
2004-08-23 |
2008-06-17 |
Wyeth Corp |
ácidos de pirrol-naftila como inibidores de pai-1
|
EP1799199B1
(de)
|
2004-10-08 |
2012-03-28 |
Novartis AG |
Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz
|
WO2006046593A1
(ja)
|
2004-10-27 |
2006-05-04 |
Daiichi Sankyo Company, Limited |
2以上の置換基を有するベンゼン化合物
|
KR20070074576A
(ko)
*
|
2004-10-29 |
2007-07-12 |
코와 가부시키가이샤 |
사구체 질환 치료제
|
EP1655298A1
(de)
*
|
2004-11-03 |
2006-05-10 |
LEK Pharmaceuticals d.d. |
Krystalline Polymorpheme Formen von Candesartan Cilexetil
|
EP1812423A1
(de)
|
2004-11-11 |
2007-08-01 |
LEK Pharmaceuticals D.D. |
Verfahren zur synthese von tetrazolen
|
KR20070084455A
(ko)
*
|
2004-11-23 |
2007-08-24 |
워너-램버트 캄파니 엘엘씨 |
지질혈증 치료용 hmg co-a 환원효소 억제제로서의7-(2h-피라졸-3-일)-3,5-디히드록시-헵탄산 유도체
|
DE102004060699A1
(de)
*
|
2004-12-16 |
2006-06-22 |
Ratiopharm Gmbh |
Verfahren zur Herstellung von Candesartan
|
EP1833801B9
(de)
*
|
2004-12-22 |
2009-02-25 |
Algry Quimica, S.L |
Zwischenprodukte für die herstellung von antagonisten des angiotensin-ii-rezeptors
|
CA2594332A1
(en)
*
|
2005-01-06 |
2006-07-13 |
Elan Pharma International Ltd. |
Nanoparticulate candesartan formulations
|
EP1836195A2
(de)
*
|
2005-01-14 |
2007-09-26 |
Teva Pharmaceutical Industries Ltd |
Herstellung von rohem candesartan-cilexetil
|
DK1843754T3
(da)
*
|
2005-01-26 |
2011-11-21 |
Lek Pharmaceuticals |
Ny farmaceutisk sammensætning indeholdende candesartan-cilexetil som lipofilt krystallinsk stof
|
DK1863801T3
(da)
*
|
2005-03-30 |
2010-11-15 |
Takeda Pharmaceutical |
Benzimidazolderivat og anvendelse deraf
|
TW200719896A
(en)
*
|
2005-04-18 |
2007-06-01 |
Astrazeneca Ab |
Combination product
|
CN100400536C
(zh)
*
|
2005-04-30 |
2008-07-09 |
重庆圣华曦药业有限公司 |
坎地沙坦酯c-型晶体的制备方法
|
EP1763525A2
(de)
|
2005-05-10 |
2007-03-21 |
Teva Pharmaceutical Industries Ltd. |
Stabiles mikronisiertes candesartan-cilexetil und herstellungsverfahren
|
EP1896455A2
(de)
|
2005-06-06 |
2008-03-12 |
Medichem, S.A. |
Verfahren zur herstellung von tetrazolylverbindungen
|
ES2264641B1
(es)
*
|
2005-06-17 |
2008-03-01 |
Quimica Sintetica, S.A. |
Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios.
|
JP2009501184A
(ja)
|
2005-07-13 |
2009-01-15 |
エフ.ホフマン−ラ ロシュ アーゲー |
5−ht6、5−ht24としてのベンゾイミダゾール誘導体
|
SI22127A
(sl)
*
|
2005-10-07 |
2007-04-30 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Postopek za pripravo kandesartan cileksetila
|
CZ299265B6
(cs)
*
|
2005-10-20 |
2008-05-28 |
Zentiva, A. S. |
Zpusob výroby 1-(cyklohexyloxykarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)bifenyl-4-yl]methyl]benzimidazol-7-karboxylátu (candesartan cilexetilu)
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
CN100344625C
(zh)
*
|
2005-12-22 |
2007-10-24 |
浙江天宇药业有限公司 |
一种制备坎地沙坦的方法
|
EP1984356B1
(de)
*
|
2006-02-15 |
2012-11-14 |
Mylan Laboratories Limited |
Verbessertes verfahren für die zubereitung von candesartan cilexetil
|
CN101024643A
(zh)
|
2006-02-20 |
2007-08-29 |
上海艾力斯医药科技有限公司 |
咪唑-5-羧酸类衍生物、制备方法及其应用
|
WO2008035360A2
(en)
*
|
2006-06-13 |
2008-03-27 |
Alembic Limited |
Novel crystalline forms of candesartan cilexetil, candesartan, tritylated candesartan and tritylated candesartan cilexetil
|
WO2008012371A1
(en)
*
|
2006-07-28 |
2008-01-31 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Process for the preparation of amorphous and crystalline forms of candesartan cilexetil using column chromatography
|
CN101528262A
(zh)
|
2006-08-10 |
2009-09-09 |
武田药品工业株式会社 |
药物组合物
|
EP2068841B1
(de)
|
2006-10-05 |
2018-09-26 |
Santarus, Inc. |
Neuartige formulierungen von protonenpumpenhemmern und verfahren zu ihrer verwendung
|
EP1908469A1
(de)
|
2006-10-06 |
2008-04-09 |
Boehringer Ingelheim Vetmedica Gmbh |
Angiotensin II Rezeptor Antagonisten zur Behandlung von systemischen Krankheiten bei Katzen
|
US8143435B2
(en)
*
|
2006-10-10 |
2012-03-27 |
Mylan Laboratories Ltd. |
One pot process for the preparation of candesartan
|
US20080103169A1
(en)
|
2006-10-27 |
2008-05-01 |
The Curators Of The University Of Missouri |
Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
|
ES2315141B1
(es)
*
|
2006-11-23 |
2009-12-22 |
Quimica Sintetica, S.A |
Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
|
ES2382009T3
(es)
|
2006-12-01 |
2012-06-04 |
Bristol-Myers Squibb Company |
Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
|
WO2008067687A1
(fr)
|
2006-12-06 |
2008-06-12 |
Shanghai Allist Pharmaceutical., Inc. |
Sels de dérivés d'acide imidazol-5-carboxylique, procédés de préparation et utilisation
|
CN101214242A
(zh)
|
2007-01-05 |
2008-07-09 |
上海艾力斯医药科技有限公司 |
新的药用组合物
|
EP1952806A1
(de)
|
2007-02-01 |
2008-08-06 |
Helm AG |
Herstellungsverfahren für Candesartan-Adsorbate
|
TW200838501A
(en)
*
|
2007-02-02 |
2008-10-01 |
Theravance Inc |
Dual-acting antihypertensive agents
|
US8242151B2
(en)
|
2007-02-07 |
2012-08-14 |
Kyowa Hakko Kirin Co., Ltd. |
Tricyclic compounds
|
US20080194307A1
(en)
*
|
2007-02-13 |
2008-08-14 |
Jeff Sanger |
Sports-based game of chance
|
CA2679446C
(en)
|
2007-03-01 |
2016-05-17 |
Probiodrug Ag |
New use of glutaminyl cyclase inhibitors
|
DE602008002371D1
(de)
*
|
2007-03-08 |
2010-10-14 |
Teva Pharma |
Pharmazeutische zusammensetzung mit candesartan-cilexetil
|
CL2008000868A1
(es)
*
|
2007-03-28 |
2008-10-10 |
Takeda Pharmaceutical |
Composicion farmaceutica solida que comprende un compuesto derivado de benzimidazol y un agente de control de ph; metodo de estabilizacion y de mejoramiento de la disolucion; uso de un agente de control de ph.
|
US9656991B2
(en)
|
2007-04-18 |
2017-05-23 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
SI22488A
(sl)
*
|
2007-04-24 |
2008-10-31 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Kristalni 1-(cikloheksiloksikarboniloksi)etil 1-((2'-cianobifenil-4-il)metil) - 2-etoksi-1h-benz(d)imidazol -7-karboksilat in proces za njegovo pripravo
|
TWI448284B
(zh)
*
|
2007-04-24 |
2014-08-11 |
Theravance Inc |
雙效抗高血壓劑
|
EP1985287A3
(de)
|
2007-04-25 |
2009-04-29 |
Teva Pharmaceutical Industries Ltd. |
Pharmazeutischer Hilfsstoffkomplex
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
EP2170930B3
(de)
|
2007-06-04 |
2013-10-02 |
Synergy Pharmaceuticals Inc. |
Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
|
TWI406850B
(zh)
*
|
2007-06-05 |
2013-09-01 |
Theravance Inc |
雙效苯并咪唑抗高血壓劑
|
EP2170868A1
(de)
*
|
2007-07-11 |
2010-04-07 |
Alembic Limited |
Verbessertes verfahren zur herstellung von candesartancilexetil
|
JP2010538071A
(ja)
|
2007-09-07 |
2010-12-09 |
セラヴァンス, インコーポレーテッド |
二重作用性降圧剤
|
JP2011506459A
(ja)
|
2007-12-11 |
2011-03-03 |
セラヴァンス, インコーポレーテッド |
抗高血圧剤としての二重作用性ベンゾイミダゾール誘導体およびその使用
|
EP2252274A4
(de)
|
2008-02-20 |
2011-05-11 |
Univ Missouri |
Zusammensetzung mit einer kombination aus omeprazol und lansoprazol und puffermittel sowie anwendungsverfahren
|
JP2011518884A
(ja)
|
2008-04-29 |
2011-06-30 |
セラヴァンス, インコーポレーテッド |
二重活性抗高血圧剤
|
JP2011522828A
(ja)
|
2008-06-04 |
2011-08-04 |
シナジー ファーマシューティカルズ インコーポレイテッド |
胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
|
EP2303870A4
(de)
*
|
2008-06-24 |
2011-07-20 |
Hetero Research Foundation |
Verfahren zur herstellung von candesartan-cilexetil
|
AU2009270833B2
(en)
|
2008-07-16 |
2015-02-19 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
EP2334651A2
(de)
|
2008-07-24 |
2011-06-22 |
Theravance, Inc. |
Blutdrucksenkende mittel mit dualer wirkung
|
CN101648918B
(zh)
*
|
2008-08-15 |
2013-01-09 |
联化科技股份有限公司 |
坎地沙坦酯的中间体化合物及其合成方法
|
SI2165702T1
(sl)
|
2008-09-17 |
2012-05-31 |
Helm Ag |
Stabilni in z lahkoto raztopljeni sestavki kandesartan cileksetila pripravljeni z vlažno granulacijo
|
WO2010042714A1
(en)
*
|
2008-10-10 |
2010-04-15 |
Janssen Pharmaceutica Nv |
Combination therapy comprising angiotensin receptor blockers and vasopressin receptor antagonists
|
KR100995755B1
(ko)
|
2008-10-31 |
2010-11-19 |
일동제약주식회사 |
트리틸 칸데사르탄 실렉세틸의 개선된 제조방법
|
DE102008059206A1
(de)
|
2008-11-27 |
2010-06-10 |
Bayer Schering Pharma Aktiengesellschaft |
Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
|
WO2010075347A2
(en)
|
2008-12-23 |
2010-07-01 |
Takeda Pharmaceutical Company Limited |
Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
|
WO2010093601A1
(en)
|
2009-02-10 |
2010-08-19 |
Metabasis Therapeutics, Inc. |
Novel sulfonic acid-containing thyromimetics, and methods for their use
|
JP5833000B2
(ja)
|
2009-07-07 |
2015-12-16 |
セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー |
二重に作用するピラゾール抗高血圧症薬
|
US8372984B2
(en)
|
2009-07-22 |
2013-02-12 |
Theravance, Inc. |
Dual-acting oxazole antihypertensive agents
|
MX2012002993A
(es)
|
2009-09-11 |
2012-04-19 |
Probiodrug Ag |
Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
|
WO2011080684A1
(en)
|
2009-12-31 |
2011-07-07 |
Ranbaxy Laboratories Limited |
Process for the preparation of candesartan cilexetil
|
WO2011090929A1
(en)
|
2010-01-19 |
2011-07-28 |
Theravance, Inc. |
Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
|
WO2011092666A1
(en)
|
2010-01-29 |
2011-08-04 |
Ranbaxy Laboratories Limited |
An improved process for the preparation of candesartan cilexetil, polymorphic forms of n-trityl candesartan and their uses thereof
|
WO2011107530A2
(en)
|
2010-03-03 |
2011-09-09 |
Probiodrug Ag |
Novel inhibitors
|
JP5688745B2
(ja)
|
2010-03-10 |
2015-03-25 |
プロビオドルグ エージー |
グルタミニルシクラーゼ(qc、ec2.3.2.5)の複素環阻害剤
|
EP2560953B1
(de)
|
2010-04-21 |
2016-01-06 |
Probiodrug AG |
Hemmer der glutaminylzyklase
|
CN101880241B
(zh)
*
|
2010-07-14 |
2013-04-17 |
浙江美诺华药物化学有限公司 |
一锅法制备2-(取代苯基)甲氨基-3-硝基苯甲酸甲酯的方法
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
KR101251741B1
(ko)
*
|
2010-12-16 |
2013-04-05 |
동화약품주식회사 |
칸데사르탄실렉세틸의 개선된 제조방법
|
ES2570167T3
(es)
|
2011-03-16 |
2016-05-17 |
Probiodrug Ag |
Derivados de benzimidazol como inhibidores de glutaminil ciclasa
|
CN102198129B
(zh)
*
|
2011-03-22 |
2016-03-30 |
浙江华海药业股份有限公司 |
含有坎地沙坦酯和氢氯噻嗪的口服片剂
|
CN102206186A
(zh)
*
|
2011-04-18 |
2011-10-05 |
张家港市信谊化工有限公司 |
坎地沙坦环合物的制备方法
|
EP2747757A1
(de)
|
2011-08-26 |
2014-07-02 |
Wockhardt Limited |
Verfahren zur behandlung kardiovaskulärer erkrankungen
|
WO2013041944A1
(en)
|
2011-09-19 |
2013-03-28 |
Ranbaxy Laboratories Limited |
Process for the preparation of micronized candesartan cilexetil
|
JP5850697B2
(ja)
*
|
2011-10-18 |
2016-02-03 |
株式会社トクヤマ |
カンデサルタンシレキセチルの製造方法
|
BR112014014527A2
(pt)
|
2011-12-15 |
2017-06-13 |
Takeda Pharmaceuticals Usa Inc |
combinações de azilsartan e clorotalidona para tratar hipertensão em pacientes negros
|
CN102391254B
(zh)
*
|
2011-12-16 |
2013-03-13 |
珠海润都制药股份有限公司 |
一种坎地沙坦的制备方法
|
CN103304543A
(zh)
*
|
2012-03-12 |
2013-09-18 |
邓俐丽 |
一种坎地沙坦酯的制备方法
|
CN102633816A
(zh)
*
|
2012-03-30 |
2012-08-15 |
李莎 |
头孢西丁酯化前体药物化合物及口服制剂
|
EP2844250B1
(de)
|
2012-05-01 |
2017-11-08 |
Translatum Medicus Inc. |
Verfahren zur behandlung und diagnose von erblindenden augenerkrankungen
|
KR20150007297A
(ko)
|
2012-05-07 |
2015-01-20 |
바이엘 파마 악티엔게젤샤프트 |
니페디핀 및 칸데사르탄 실렉세틸을 포함하는 제약 투여 형태의 제조 방법
|
US20140134187A1
(en)
|
2012-06-25 |
2014-05-15 |
The Johns Hopkins University |
Therapeutic and diagnostic methods for autism spectrum disorders and other conditions
|
JP6218084B2
(ja)
|
2012-10-04 |
2017-10-25 |
国立研究開発法人国立循環器病研究センター |
悪性腫瘍転移抑制用医薬
|
CN102952040A
(zh)
*
|
2012-11-20 |
2013-03-06 |
峨眉山天梁星制药有限公司 |
一种坎地沙坦酯中间体的硝基还原为氨基的方法
|
PL236001B1
(pl)
|
2012-12-21 |
2020-11-30 |
Adamed Spolka Z Ograniczona Odpowiedzialnoscia |
Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
WO2014151206A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
US9339542B2
(en)
*
|
2013-04-16 |
2016-05-17 |
John L Couvaras |
Hypertension reducing composition
|
JP2016516804A
(ja)
|
2013-04-17 |
2016-06-09 |
ファイザー・インク |
心血管疾患を治療するためのn−ピペリジン−3−イルベンズアミド誘導体
|
EP3004138B1
(de)
|
2013-06-05 |
2024-03-13 |
Bausch Health Ireland Limited |
Ultrareine agonisten von guanylatcyclase c, verfahren zur herstellung und verwendung davon
|
EP3025711B1
(de)
|
2013-07-23 |
2020-11-18 |
Daiichi Sankyo Company, Limited |
Medikament zur vorbeugung oder behandlung von hypertonie
|
CN104098550A
(zh)
*
|
2014-07-17 |
2014-10-15 |
浙江华海药业股份有限公司 |
一种精制三苯甲基坎地沙坦的方法
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
EP3312174B1
(de)
*
|
2015-06-05 |
2019-12-18 |
Zhejiang Huahai Pharmaceutical Co., Ltd |
Verfahren zur herstellung von tritylcandesartan
|
CZ2015687A3
(cs)
|
2015-10-02 |
2017-04-12 |
Zentiva, K.S. |
Farmaceutická kompozice obsahující kombinaci kandesartanu, amlodipinu a hydrochlorthiazidu
|
EP3219309A1
(de)
|
2016-03-17 |
2017-09-20 |
K.H.S. Pharma Holding GmbH |
Pharmazeutische zusammensetzung mit fixdosierungskombination von amlodipin, candesartan cilexetil und hydrochlorothiazid zur behandlung von bluthochdruck
|
EP3434284A4
(de)
|
2016-03-24 |
2019-11-13 |
Daiichi Sankyo Company, Limited |
Medizin zur behandlung von nierenerkrankung
|
CN106432201B
(zh)
*
|
2016-09-14 |
2019-04-23 |
威海迪素制药有限公司 |
一种坎地沙坦酯结晶的制备方法
|
JP7050893B2
(ja)
|
2017-07-07 |
2022-04-08 |
ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー |
ネコの全身性疾患の予防又は治療用アンジオテンシンii受容体拮抗薬
|
ES2812698T3
(es)
|
2017-09-29 |
2021-03-18 |
Probiodrug Ag |
Inhibidores de glutaminil ciclasa
|
WO2019200181A1
(en)
|
2018-04-11 |
2019-10-17 |
Ohio State Innovation Foundation |
Methods and compositions for sustained release microparticles for ocular drug delivery
|
WO2020140193A1
(zh)
|
2019-01-02 |
2020-07-09 |
临海市华南化工有限公司 |
一种坎地沙坦酯中间体的合成方法
|
EP3911648A4
(de)
|
2019-01-18 |
2022-10-26 |
Astrazeneca AB |
Pcsk9-inhibitoren und verfahren zur verwendung davon
|
CN110514758A
(zh)
*
|
2019-08-21 |
2019-11-29 |
天地恒一制药股份有限公司 |
一种坎地沙坦酯有关物质的检测方法
|
EP3984989A4
(de)
*
|
2020-08-13 |
2023-11-22 |
Nanjing Heron Pharmaceutical Science and Technology Co., Ltd. |
Ibuprofenester-prodrug, pharmazeutische zusammensetzung sowie herstellungsverfahren und verwendung
|
US11655220B2
(en)
|
2020-10-22 |
2023-05-23 |
Hetero Labs Limited |
Process for the preparation of angiotensin II receptor blockers
|
EP4052695A1
(de)
|
2021-03-05 |
2022-09-07 |
Midas Pharma GmbH |
Stabile orale pharmazeutische zusammensetzungen mit fester dosis und sofortiger freisetzung mit amlodipin, atorvastatin und candesartan cilexetil
|
WO2023285646A1
(en)
|
2021-07-15 |
2023-01-19 |
Adamed Pharma S.A |
A pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
|
CN114149414B
(zh)
*
|
2021-12-23 |
2023-08-04 |
浙江永宁药业股份有限公司 |
一种利用微反应器连续流制备坎地沙坦的方法
|
WO2024075017A1
(en)
|
2022-10-04 |
2024-04-11 |
Zabirnyk Arsenii |
Inhibition of aortic valve calcification
|
EP4374855A1
(de)
|
2022-11-22 |
2024-05-29 |
KRKA, D.D., Novo Mesto |
Pharmazeutische darreichungsform von candesartan und indapamid
|